United States FDA Approves NM8074 (Ruxoprubart) IND for Treating Dermatomyositis (DM): A Chronic Inflammatory Disorder of the Skin
--- The United States FDA Approves the Initiation for Phase II Efficacy…
FDA Approves Samsung Bioepis OSPOMYV, XBRYK (denosumab-dssb), a Biosimilar to Prolia and Xgeva
OSPOMYV™ and XBRYK™ approved by the U.S. Food and Drug Administration (FDA)…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
VL E-GOVERNANCE & IT SOLUTIONS LIMITED APPROVES ALLOTMENT OF 5.34 CRORE WARRANTS, AMOUNTING TO RS. 400.99 CRORE ON A PREFERENTIAL BASIS
Board approved the allotment of 5.34 Crore Fully Convertible Warrants ("Warrants") each…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…